REAL-WORLD ASSOCIATIONS BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND DIABETIC RETINOPATHY ACCOUNTING FOR LONGITUDINAL GLYCEMIC CONTROL
GLP-1 RA users were at a reduced risk of developing DR, DME, and treatment-requiring DR/DME. GLP-1 RA agents are likely protective of poor visual outcomes, though further research is needed to determine whether these medications remain protective when initiated after DR development.
Authors
- Anne Louise Coleman (ORCID: https://orcid.org/0000-0002-0807-5176)
- Irena Tsui (ORCID: https://orcid.org/0000-0001-7989-5174)
- Reza Talebı (ORCID: https://orcid.org/0000-0001-9109-7677)
- Blake H. Fortes (ORCID: https://orcid.org/0000-0002-3206-0062)
- Fei Yu (ORCID: https://orcid.org/0000-0002-2824-9866)
Institutions
- Thomas Jefferson University (US)
- University of California, Los Angeles (US)
- UCLA Health (US)
- Doheny Eye Institute (US)
Publication Details
- Journal
- Retina
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1097/iae.0000000000004507
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.12